Olaparib plus Trastuzumab in HER2[+] BRCA-Mutated Advanced Breast Cancer Patients: The OPHELIA Study

被引：0
|
作者：
Ales-Martinez, Jose E.
Balmana, Judith
Sanchez-Rovira, Pedro
Bofill, Francisco Javier Salvador
Garcia-Saenz, Jose Angel
Pimentel, Isabel
Murillo, Serafin Morales
Fernandez, Adela
Martinez, Ainhara Lahuerta
Ferrer, Neus
Zamora, Pilar
Bermejo, Begona
Diaz-Redondo, Tamara
Lopez-Ceballos, Maria Helena
Galan, Maria
Malfettone, Andrea
Calabuig, Laura
Sampayo-Cordero, Miguel
Perez-Garcia, Jose Manuel
Cortes, Javier
Llombart-Cussac, Antonio
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P4-07-29
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-07-29
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Effectiveness of olaparib plus trastuzumab in HER2[+], BRCA-mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study
    Ales-Martinez, J. E.
    Morales, S.
    Fernandez Abad, M.
    Sanchez-Rovira, P.
    Salvador Bofill, F. J.
    Lahuerta, A.
    Garcia-Saenz, J. A.
    Garau Llinas, I.
    Diaz Redondo, T.
    Ferrer, N.
    Caranana, V.
    Lopez, R.
    Alonso Soler, S. E.
    Bermejo, B.
    de la Haba, J.
    Zamora, P.
    Balmana, J.
    Lopez-Miranda, E.
    Cortes, J.
    Llombart Cussac, A.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 139 - +
  • [2] Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study
    Ales-Martinez, Jose Enrique
    Balmana, Judith
    Sanchez-Rovira, Pedro
    Bofill, Francisco Javier Salvador
    Saenz, Jose Angel Garcia
    Pimentel, Isabel
    Morales, Serafin
    Fernandez-Abad, Maria
    Martinez, Ainhara Lahuerta
    Ferrer, Neus
    Zamora, Pilar
    Bermejo, Begona
    Diaz-Redondo, Tamara
    Lopez-Ceballos, Maria Helena
    Galan, Maria
    Perez-Escuredo, Jhudit
    Calabuig, Laura
    Sampayo, Miguel
    Perez-Garcia, Jose Manuel
    Cortes, Javier
    Llombart-Cussac, Antonio
    [J]. BREAST, 2024, 77
  • [3] Olaparib for BRCA-mutated advanced ovarian cancer
    de Lartigue, Jane
    [J]. JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (06): : 206 - 208
  • [4] Adjuvant Olaparib in BRCA-Mutated Breast Cancer
    Hoshi, Aoi
    Bando, Hiroko
    Sekine, Ikuo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15): : 1439 - 1440
  • [5] Olaparib for the treatment of BRCA-mutated advanced ovarian cancer
    Munroe, Marklie
    Kolesar, Jill
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (14) : 1037 - 1041
  • [6] Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer
    Narod, Steven
    Booth, Christopher M.
    Foulkes, William D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (18): : 1792 - 1792
  • [7] Adjuvant Olaparib in BRCA-Mutated Breast Cancer REPLY
    Tutt, Andrew N. J.
    Garber, Judy E.
    Geyer, Charles E., Jr.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15): : 1440 - 1440
  • [8] Talazoparib for BRCA-mutated advanced breast cancer
    Gunjur, Ashray
    [J]. LANCET ONCOLOGY, 2018, 19 (10): : E511 - E511
  • [9] Lurbinectedin for BRCA-mutated advanced breast cancer
    Gourd, Elizabeth
    [J]. LANCET ONCOLOGY, 2018, 19 (11): : E582 - E582
  • [10] Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
    Spring, Laura M.
    Han, Hyo
    Liu, Minetta C.
    Hamilton, Erika
    Irie, Hanna
    Santa-Maria, Cesar A.
    Reeves, James
    Pan, Peng
    Shan, Ming
    Tang, Yongqiang
    Graham, Julie R.
    Hazard, Sebastien
    Ellisen, Leif W.
    Isakoff, Steven J.
    [J]. NATURE CANCER, 2022, 3 (08) : 927 - +
12345